Novel Evaluations of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Men Compared to Age Group-Matched Transgender Women and Cisgender Adults
This study is examining how gender-affirming hormone therapy affects the health of blood vessels and impacts cardiovascular disease risk in transgender men.
Transgender men (i.
e., assigned female at birth but identify as male) taking
testosterone
o Ages 18 to 40 or 50 to 75 years
o In good general health
o Have been on hormones for at least 1 year
o No history of gonadectomy
o No history of cancer, diabetes or heart disease
o Non-smoker (or quit at least one year ago)
Main Procedures Involved: • Blood tests for hormones, cholesterol, clotting factor and other labs
• Blood vessel cell collection
• Dietary analysis
• Physical activity monitor
• Questionnaires
• Ultrasound of the blood vessels
• Measurements of bone mineral density and body composition
• Compensation provided
Adult
Observational
Local
Compensation provided
Sean Iwamoto, MD
Protocol Number: 19-2323
More information available at ClinicalTrials.gov: NCT04237467
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers